Navigation Links
Denosumab delays development of prostate cancer bone metastasis
Date:11/15/2011

An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer. The study, receiving Online First publication in The Lancet, is the first to successfully reduce bone metastasis in such patients and supports the importance of targeting the bone microenvironment to prevent prostate tumor spread.

"Prostate cancer patients who develop bone metastases usually have poor outcomes, so preventing the development of metastasis has been a major unmet clinical need," says Matthew Smith, MD, PhD, of the MGH Cancer Center, lead and corresponding author of the Lancet paper. "This first demonstration of a treatment that can meet that goal is a significant accomplishment that should lead to better treatment strategies."

Bone is the most common site in some patients the only site for the development of prostate cancer metastases, which can lead to pain, fractures and the need for surgery or radiation therapy. Almost all men who die from prostate cancer have bone metastasis. Previous research has suggested that metastatic development involves interactions between tumor-secreted growth factors and the normal process by which bone tissue is broken down and rebuilt. Animal studies have indicated that inhibiting osteoclasts cells that cause the resorption of bone can prevent metastasis and that expression on cancer cells of a signalling protein called RANKL, which activates osteoclasts, may prepare the bone microenvironment for tumor spread.

Denosumab is a monoclonal antibody against RANKL and is FDA approved for two uses treatment of osteoporosis and prevention of fractures in patients with bone metastases from solid tumors. Denosumab is marketed by Amgen which supported the current study under the brand names Prolia for osteoporosis treatment and Xgeva for cancer treatment. The current study enrolled 1,432 participants at 319 centers in 30 countries all prostate cancer patients whose tumors had stopped responding to androgen-deprivation therapy and were metastasis-free, although rising PSA levels indicated they were at risk for metastasis.

Participants were randomly assigned to receive injections of either denosumab or a placebo every four weeks. During the two-year study period, patients were examined including a bone scan every four months, and X-ray skeletal surveys performed annually. If a bone scan indicated the presence of metastasis, it was confirmed with either X-ray, CT scan or MRI. After that confirmation, study treatment was discontinued, since other therapies are approved to treat metastatic prostate cancer.

Study results indicated that denosumab treatment increased bone-metastasis-free survival defined as the time to either the first metastasis or death from any cause by an average of more than four months, extended the time to first metastasis and delayed symptoms of metastasis. Biochemical markers indicated that denosumab treatment did reduce bone turnover. While there was no survival difference between the two study groups, the authors note that that fact that denosumab was discontinued when the first metastasis was diagnosed makes judging the drug's effects on survival difficult.


'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Denosumab delayed time to first skeletal-related side effect
2. Toronto researchers find first physical evidence bilingualism delays onset of Alzheimers symptoms
3. Folic Acid in Pregnancy May Prevent Kids Language Delays
4. New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients
5. Phase II study shows new cancer drug combination significantly delays breast cancer progression
6. Emergency treatment for heart attack improving but delays still occur
7. ADHD Drug Delays Puberty in Male Monkeys, Study Finds
8. One-Third of Severe Heart Attack Patients Have Treatment Delays
9. Many Pediatricians Arent Testing Tots for Developmental Delays
10. Hospital Delays Tied to Racial Divide in Heart Attack Care
11. Delays in Hospital Transfers for Heart Attack Patients May Raise Death Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... TLC Laser Eye Centers ... California. The laser eye center will now be called “Gordon Schanzlin New Vision Institute, ... will remain at the full-service facility to ensure that patients continue to receive the ...
(Date:5/5/2016)... Stockholm/San Jose (PRWEB) , ... May 05, 2016 , ... ... the art of self-love. Every day, LELO fans reach out via email, social media ... recurring question keeps upcoming up: “Is the way I masturbate ‘normal’ or ‘correct’?” , ...
(Date:5/5/2016)... Collins, CO (PRWEB) , ... May 05, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been named as ... the American Institute of Architects and the Academy of Architecture for Health. The building, ... Harrell Architects, opened to patients in October of 2014. , The ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... Jennifer Drago presented a talk highlighting the organization’s successful Care Transitions ... Chicago. , The talk was titled “Minimizing Costs in the Post-Acute Environment Through ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... -- Research and Markets has announced the addition ... USA"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Positron Emission Tomography (PET) scanner and cyclotron install base ... with the current known number of PET scanners and ... report also contains a detailed breakdown of this equipment ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Diversified Holdings (NYSE: CODI ) ("CODI," "we," ... market businesses, announced today its consolidated operating results for ... First Quarter 2016 Highlights , Generated Cash Flow ... of $13.6 million for the first quarter of 2016; ... the first quarter of 2016; , Paid a ...
Breaking Medicine Technology: